Bio Europe – Virtual, Starting October 25
With over 40 clients and a growing number of engagements in Europe, EVERSANA™ is the leading the way as the only end-to-end provider of commercialisation services that span all stages of the product life cycle to deliver long-term value for patients, physicians and payers.
Join our team for virtual networking during Bio Europe or watch our “Collaboration Close-Up” session, in partnership with Shorla Pharma.
Launching in today’s unpredictable market is a journey with new challenges around every corner. While the oncology pipeline is rapidly growing, stringent competition and an evolving provider environment are putting intense pressure on manufacturers to build effective commercialization infrastructures and launch products at unprecedented speeds, which comes at a steep price.
In this session Shorla Pharma, a specialty pharmaceutical company, will share their partnership journey with EVERSANA to bypass the traditional commercialization model that’s too inefficient, costly and cumbersome – and share their vision of an integrated model that’s streamlined, it maximizes brand value and improves patient access and outcomes.
Sharon Cunningham, CEO, Shorla Pharma
Mike Ryan, Executive Vice President, Europe, EVERSANA
Stay current with the latest commercialisation news:
Shorla Pharma Announces Partnership with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment
EVERSANA™ expands medical information and integrated compliance services across Europe
Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada
Assess Commercial Readiness in Europe